

the required fee; (7) a revised form PTO 1449; and (8) copies of references BE-BP listed on the revised form PTO 1449.

It is estimated that no additional fee is necessary for filing this amendment. In the event that an additional fee is required, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

**IN THE CLAIMS:**

Please amend claims 1, 4 and 20-22 to read as follows:

1. (amended) A recombinant influenza virus the genome of which contains a region encoding a tumor antigen.
4. (twice amended) The recombinant influenza virus of Claim 1, 20, 21, 22, 23, 24 or 25 in which the region encoding the tumor antigen is in a bicistronic arrangement with an influenza virus gene.
20. (amended) The recombinant influenza virus of Claim 1, wherein the tumor antigen is a human tumor antigen recognized by T lymphocytes.
21. (amended) The recombinant influenza virus of Claim 20, wherein the human tumor antigen is a melanocyte tumor antigen.
22. (amended) The recombinant influenza virus of Claim 20, wherein the human tumor antigen is a breast, ovarian, cervical or pancreatic carcinoma antigen.

**REMARKS**

Claims 1-5 and 20-29 are pending in the instant application. Applicants note that Claims 23-27, drawn to non-elected inventions, have been withdrawn from consideration. In order to expedite the prosecution of the application, Applicants have amended claims 1, 4, and 20-22 to make grammatical corrections and/or to clarify terminology used in the claims. In particular, Applicants have amended claims 1, 4 and 20 by replacing the term "tumor-